Abstract HTML Views: 385 PDF Downloads: 374 Total Views/Downloads: 1071
Abstract HTML Views: 231 PDF Downloads: 289 Total Views/Downloads: 702
Rationale and aim:
Nasal congestion is a common symptom in allergic and non-allergic rhinitis, rhinosinusitis
and nasal polyposis. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this
study was to evaluate the clinical effectiveness efficacy of Narivent®, which is an osmotically acting medical device with
anti-oedematous and anti-inflammatory effects, in a long-term (30 days) treatment.
A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian
Otolaryngology Department of 56 both genders patients with persistent nasal congestion.
Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 4 weeks. The severity of symptoms
was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms
and signs. Differences in subjective and objective severity measures before and after treatment were compared using
Paired-Sample Wilcoxon Signed Rank Test.
A significant improvement after treatment (p<0.001) has been recorded for the main subjective symptoms and
objective signs (overall symptom burden, nasal congestion, cephalea, rhinorrhea, hyposmia, turbinates hypertrophy, mucosa
Study results confirm the efficacy of Narivent® in treating nasal congestion over a 4 weeks period.